PE20240367A1 - Forma cristalina iv del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma - Google Patents
Forma cristalina iv del compuesto agonista de receptor de melanocortina y metodo de preparacion para la mismaInfo
- Publication number
- PE20240367A1 PE20240367A1 PE2023001516A PE2023001516A PE20240367A1 PE 20240367 A1 PE20240367 A1 PE 20240367A1 PE 2023001516 A PE2023001516 A PE 2023001516A PE 2023001516 A PE2023001516 A PE 2023001516A PE 20240367 A1 PE20240367 A1 PE 20240367A1
- Authority
- PE
- Peru
- Prior art keywords
- preparation
- crystalline form
- receptor agonist
- melanocortin receptor
- agonist compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
SE REFIERE A LA FORMA CRISTALINA IV DEL HIDRATO DE CLORHIDRATO DE N-((3S,5S)-1-((3S,4R)-1-(TER-BUTIL)-4-(4-CLOROFENIL)PIRROLIDIN-3-CARBONIL)-5-(MORFOLIN-4-CARBONIL)-PIRROLIDIN-3-IL)-N-((1S,4R)-4-METILCICLOHEXIL)ISOBUTIRAMIDA CUYO PATRON DE DIFRACCION DE POLVO DE RAYOS X PRESENTA PICOS CARACTERISTICOS CON LOS SIGUIENTES ANGULOS DE DIFRACCION (VALORES 2THETA) DE: 7.76±0.2°, 9.69±0.2°, 10.12±0.2°, 10.63±0.2°, 11.93±0.2°, 12.72±0.2°, 14.57±0.2°, 16.07±0.2°, 17.65±0.2°, 18.24±0.2°, 19.10±0.2°, 19.62±0.2°, 20.09±0.2°, 21.19±0.2°, 21.62±0.2°, 22.02±0.2°, 22.25±0.2°, 22.61±0.2°, 23.59±0.2°, 24.26±0.2°, 24.78±0.2°, 25.29±0.2°, 26.15±0.2°, 28.52±0.2°, 29.38±0.2° y 29.98±0.2°. TAMBIEN SE REFIERE A UN METODO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA QUE LO COMPRENDE. DICHO COMPUESTO ES AGONISTA DEL RECEPTOR DE MELANOCORTINA-4 (MC4R) SIENDO UTIL EN EL TRATAMIENTO DE OBESIDAD, DIABETES.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200142400 | 2020-10-29 | ||
| PCT/KR2021/015475 WO2022092914A1 (ko) | 2020-10-29 | 2021-10-29 | 멜라노코르틴 수용체 작용제 화합물의 결정형 ⅳ 및 이의 제조방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240367A1 true PE20240367A1 (es) | 2024-03-04 |
Family
ID=81384123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023001516A PE20240367A1 (es) | 2020-10-29 | 2021-10-29 | Forma cristalina iv del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240010633A1 (es) |
| EP (1) | EP4219475A4 (es) |
| JP (2) | JP2023548161A (es) |
| KR (2) | KR102672627B1 (es) |
| CN (1) | CN116507614A (es) |
| AU (1) | AU2021367714B2 (es) |
| CA (1) | CA3195328A1 (es) |
| CL (1) | CL2023001225A1 (es) |
| CO (1) | CO2023006521A2 (es) |
| IL (1) | IL302429A (es) |
| MX (1) | MX2023004731A (es) |
| PE (1) | PE20240367A1 (es) |
| WO (1) | WO2022092914A1 (es) |
| ZA (1) | ZA202305590B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI754448B (zh) * | 2019-11-07 | 2022-02-01 | 南韓商Ｌｇ化學股份有限公司 | 黑皮質素-4受體激動劑 |
| EP4249485A4 (en) * | 2020-12-22 | 2024-05-15 | Lg Chem, Ltd. | CRYSTALLINE FORM III OF A MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD OF PREPARING THE SAME |
| TWI814185B (zh) * | 2020-12-22 | 2023-09-01 | 南韓商Ｌｇ化學股份有限公司 | 黑皮質素受體促效劑化合物之晶型ii及其製備方法 |
| AU2021409684B2 (en) * | 2020-12-22 | 2025-06-26 | Lg Chem, Ltd. | Use as selective agonist of malanocortin-4 receptor |
| JP2024500966A (ja) * | 2020-12-22 | 2024-01-10 | エルジー・ケム・リミテッド | メラノコルチン受容体アゴニスト化合物の結晶形ｉおよびその製造方法 |
| KR102854596B1 (ko) * | 2021-05-06 | 2025-09-03 | 주식회사 엘지화학 | 멜라노코르틴 수용체 작용제 화합물의 결정형 ⅶ 및 이의 제조방법 |
| AU2022271119A1 (en) * | 2021-05-06 | 2023-11-02 | Lg Chem, Ltd. | Crystalline form v of melanocortin receptor agonist compound, and method for preparing same |
| WO2022235103A1 (ko) * | 2021-05-07 | 2022-11-10 | 주식회사 엘지화학 | 멜라노코르틴 수용체 작용제 화합물의 황산염의 결정형 및 이의 제조방법 |
| EP4317151A4 (en) * | 2021-05-07 | 2024-10-30 | Lg Chem, Ltd. | CRYSTAL FORM IV OF ORGANIC ACID SALTS OF A MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD OF PREPARING THE SAME |
| JP2024516739A (ja) * | 2021-05-07 | 2024-04-16 | エルジー・ケム・リミテッド | メラノコルチン受容体アゴニスト化合物とバニリンの共結晶およびその製造方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003505435A (ja) * | 1999-06-04 | 2003-02-12 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−４受容体ゴニストとしての置換ピペリジン |
| JP2004521117A (ja) * | 2001-01-23 | 2004-07-15 | イーライ・リリー・アンド・カンパニー | メラノコルチン受容体アゴニストとしての置換ピペリジン／ピペラジン |
| AR044510A1 (es) | 2003-04-14 | 2005-09-14 | Merck & Co Inc | Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina |
| TWI341835B (en) * | 2003-11-12 | 2011-05-11 | Lg Life Sciences Ltd | Melanocortin receptor agonists |
| TWI332501B (en) * | 2006-07-14 | 2010-11-01 | Lg Life Sciences Ltd | Melanocortin receptor agonists |
| KR20080007046A (ko) * | 2006-07-14 | 2008-01-17 | 주식회사 엘지생명과학 | 멜라노코틴 수용체의 항진제 |
| UA99555C2 (en) * | 2008-11-12 | 2012-08-27 | Элджи Лайф Саенсез Лтд. | Melanocortin receptor agonists |
| AU2018219880A1 (en) | 2017-02-08 | 2019-08-29 | Tilray, Inc. | Methods and apparatus for low-pressure radiant energy processing of cannabis |
| TWI754448B (zh) * | 2019-11-07 | 2022-02-01 | 南韓商Ｌｇ化學股份有限公司 | 黑皮質素-4受體激動劑 |
-
2021
- 2021-10-29 CA CA3195328A patent/CA3195328A1/en active Pending
- 2021-10-29 IL IL302429A patent/IL302429A/en unknown
- 2021-10-29 KR KR1020210146191A patent/KR102672627B1/ko active Active
- 2021-10-29 JP JP2023526431A patent/JP2023548161A/ja active Pending
- 2021-10-29 US US18/251,111 patent/US20240010633A1/en active Pending
- 2021-10-29 CN CN202180073211.6A patent/CN116507614A/zh active Pending
- 2021-10-29 MX MX2023004731A patent/MX2023004731A/es unknown
- 2021-10-29 AU AU2021367714A patent/AU2021367714B2/en active Active
- 2021-10-29 EP EP21886908.9A patent/EP4219475A4/en active Pending
- 2021-10-29 WO PCT/KR2021/015475 patent/WO2022092914A1/ko not_active Ceased
- 2021-10-29 PE PE2023001516A patent/PE20240367A1/es unknown
-
2023
- 2023-04-27 CL CL2023001225A patent/CL2023001225A1/es unknown
- 2023-05-17 CO CONC2023/0006521A patent/CO2023006521A2/es unknown
- 2023-05-24 ZA ZA2023/05590A patent/ZA202305590B/en unknown
-
2024
- 2024-05-31 KR KR1020240071411A patent/KR20240085233A/ko active Pending
-
2025
- 2025-04-02 JP JP2025061441A patent/JP2025098275A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023001225A1 (es) | 2023-11-03 |
| MX2023004731A (es) | 2023-05-10 |
| AU2021367714A1 (en) | 2023-06-01 |
| CA3195328A1 (en) | 2022-05-05 |
| KR20240085233A (ko) | 2024-06-14 |
| WO2022092914A1 (ko) | 2022-05-05 |
| CO2023006521A2 (es) | 2023-08-18 |
| IL302429A (en) | 2023-06-01 |
| ZA202305590B (en) | 2024-09-25 |
| JP2025098275A (ja) | 2025-07-01 |
| KR102672627B1 (ko) | 2024-06-07 |
| US20240010633A1 (en) | 2024-01-11 |
| JP2023548161A (ja) | 2023-11-15 |
| EP4219475A4 (en) | 2024-03-13 |
| CN116507614A (zh) | 2023-07-28 |
| AU2021367714B2 (en) | 2024-01-25 |
| EP4219475A1 (en) | 2023-08-02 |
| KR20220057473A (ko) | 2022-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240367A1 (es) | Forma cristalina iv del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma | |
| PE20240366A1 (es) | Forma cristalina iii del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma | |
| PE20240124A1 (es) | Forma cristalina ii del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma | |
| PE20240048A1 (es) | Forma cristalina i del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma | |
| PE20220766A1 (es) | Agonistas de receptor de melanocortina-4 | |
| ZA202007671B (en) | Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and biguanide hypoglycemic drug as well as preparation method and use thereof | |
| CL2019003619A1 (es) | Preparación sólida para administración oral. | |
| CL2008000127A1 (es) | Compuestos derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, inflamacion, trastornos urologicos | |
| PE20090912A1 (es) | Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen | |
| PE20180160A1 (es) | Sulfonilureas y compuestos relacionados y uso de estos | |
| PE20110060A1 (es) | Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida | |
| DE60321271D1 (de) | Transistoren und Speicherkondensatoren enthaltend eine HfO2-Zusammensetzung mit erhöhter Dielektrizitätskonstante | |
| DK1853266T3 (da) | 2S,4R-Ketoconazol til behandling af diabetes, metabolsk syndrom og øvrige tilstande | |
| AR084309A1 (es) | Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina | |
| RU2016114540A (ru) | Соль азотсодержащего гетероциклического соединения или ее кристаллическая форма, фармацевтическая композиция и ингибитор flt3 | |
| RU2010133483A (ru) | Новые кристаллические формы 4-{4-(2-адамантилкарбамоил)-5-третбутилпиразол-1-ил}бензойной кислоты | |
| EA201891413A1 (ru) | Фармацевтическая композиция, содержащая безводный дазатиниб | |
| UY38592A (es) | Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-n-(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida monohidratada, proceso para su preparación y composiciones farmacéuticas que las contienen | |
| PH12017501933A1 (en) | Bromodomain inhibitor | |
| RU2016141650A (ru) | Амидные соединения | |
| MY202100A (en) | Crystal | |
| MX392844B (es) | Formas cristalinas del antagonista del receptor cxcr7 acido (3s,4s)-1-ciclopropilmetil-4-{[5-(2,4-difluoro-fenil)-isoxazol-3-carbonil]-amino}-piperidin-3-carboxilico (1-pirimidin-2-il-ciclopropil)-amida | |
| MX379181B (es) | Cristales de derivado de amina ciclica y uso farmaceutico de los mismos. | |
| RU2019114208A (ru) | Кристаллические формы 4-(2-((1r,2r)-2-гидроксициклогексиламино)бензотиазол-6-илокси)-n-метилпиколинамида | |
| BR112023003365A2 (pt) | Composição farmacêutica em uma forma de dosagem única |